These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 21133821

  • 1. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
    Jianu CS, Fossmark R, Syversen U, Hauso Ø, Fykse V, Waldum HL.
    Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
    [Abstract] [Full Text] [Related]

  • 2. Treatment of ECL cell carcinoids with octreotide LAR.
    Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL.
    Scand J Gastroenterol; 2004 Jul; 39(7):621-8. PubMed ID: 15370681
    [Abstract] [Full Text] [Related]

  • 3. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
    Khuroo MS, Khuroo MS, Khuroo NS.
    J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
    Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, Corinaldesi R, Tomassetti P.
    Endocr Relat Cancer; 2008 Mar; 15(1):337-42. PubMed ID: 18310299
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
    Moore AR, Boyce M, Steele IA, Campbell F, Varro A, Pritchard DM.
    PLoS One; 2013 Mar; 8(10):e76462. PubMed ID: 24098507
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The gastric mucosa 25 years after proximal gastric vagotomy.
    Sagatun L, Jianu CS, Fossmark R, Mårvik R, Nordrum IS, Waldum HL.
    Scand J Gastroenterol; 2014 Oct; 49(10):1173-80. PubMed ID: 25157752
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Gastric carcinoids after long-term use of a proton pump inhibitor.
    Jianu CS, Fossmark R, Viset T, Qvigstad G, Sørdal O, Mårvik R, Waldum HL.
    Aliment Pharmacol Ther; 2012 Oct; 36(7):644-9. PubMed ID: 22861200
    [Abstract] [Full Text] [Related]

  • 17. Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue.
    Manfredi S, Pagenault M, de Lajarte-Thirouard AS, Bretagne JF.
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):1021-5. PubMed ID: 18049175
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Gastric neuroendocrine tumor].
    Díaz-Sánchez CL, Molano Romero RA, Martínez González M, Márquez Rivera ML, Halabe-Cherem J.
    Rev Gastroenterol Mex; 1998 Nov; 63(2):97-100. PubMed ID: 10068736
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.